Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology.
Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology.
复制标题
DOI：
10.3802/jgo.2014.25.1.43
复制
发表时间：
2014-01
影响因子：
3.9
通讯作者：
Kikkawa F
中科院分区：
文献类型：
--
作者：
Kajiyama H;Shibata K;Mizuno M;Umezu T;Suzuki S;Sekiya R;Niimi K;Mitsui H;Yamamoto E;Kawai M;Nagasaka T;Kikkawa F
本研究旨在探讨一线化疗对复发性卵巢癌患者的总生存率（OS）和复发后生存率（PRS）的影响，并对组织学类型进行分层。分析了574例复发性卵巢癌患者，这些患者具有足够的临床信息，包括一线化疗。通过中心病理审查评价病理切片。将患者分为两组：A组（n=261），接受紫杉烷加铂类药物治疗; B组（n=313），接受以铂类药物为基础的常规化疗，不接受紫杉烷类药物治疗。中位年龄为54岁（范围：14 - 89岁）。与B组相比，A组的中位OS（45.0个月vs. 30.3个月，p<0.001）和PRS（23.0个月vs. 13.0个月，p<0.001）显著更好。在透明细胞或粘液组织学患者中，两组的OS和PRS相似。相比之下，在非透明细胞、非粘液组织学的患者中，A组的OS和PRS显著优于B组（OS，p<0.001; PRS，p<0.001）。多变量分析显示，在非透明细胞、非粘液组织学患者中，包括紫杉烷和铂类在内的化疗是有利生存结局的独立预测因素。相反，在透明细胞或粘液组织学患者中，与不含紫杉烷类的传统铂类方案相比，含紫杉烷类的铂类联合化疗并未改善OS和PRS。自从紫杉烷加铂类药物出现以来，复发性卵巢癌患者的预后有所改善。然而，我们在这里证明，这种改善仅限于非透明细胞，非粘液组织学的患者。
This study was conducted to examine the effects of front-line chemotherapy on overall survival (OS) and postrecurrence survival (PRS) of patients with recurrent ovarian cancer, when stratifying the histologic type. Five hundred and seventy-four patients with recurrent ovarian cancer with sufficient clinical information, including front-line chemotherapy, were analyzed. The pathologic slides were evaluated by central pathologic review. The patients were divided into two groups: group A (n=261), who underwent taxane plus platinum, and group B (n=313), who underwent conventional platinum-based chemotherapy without taxanes. The median age was 54 years (range, 14 to 89 years). Group A had significantly better median OS (45.0 months vs. 30.3 months, p<0.001) and PRS (23.0 months vs. 13.0 months, p<0.001) compared to group B. The OS and PRS were similar between the groups in patients with clear cell or mucinous histology. In contrast, among patients with non-clear cell, non-mucinous histologies, the OS and PRS of group A were significantly better than those of group B (OS, p<0.001; PRS, p<0.001). Multivariable analyses revealed that, among patients with non-clear cell, non-mucinous histologies, chemotherapy including taxane and platinum was an independent predictor of favorable survival outcomes. Conversely, in patients with clear cell or mucinous histology, taxane-including platinum-based combination chemotherapy did not improve the OS and PRS compared to a conventional platinum-based regimen which did not include taxanes. Since the emergence of taxane plus platinum, the prognosis of patients with recurrent ovarian cancer has improved. However, we here demonstrate that this improvement is limited to patients with non-clear cell, non-mucinous histologies.
登录
查看更多内容
DOI：
10.1097/igc.0b013e3182070f17
发表时间：
2011-02-01
影响因子：
4.8
作者：
Rustin, Gordon John Sampson;Vergote, Ignace;Vermorken, Jan
通讯作者：
Vermorken, Jan
影响因子：
4.7
作者：
Eisenkop, SM;Friedman, RL;Wang, HJ
通讯作者：
Wang, HJ
影响因子：
6.2
作者：
Salani, Ritu;Santillan, Antonio;Bristow, Robert E.
通讯作者：
Bristow, Robert E.
影响因子：
45.3
作者：
Dizon, DS;Hensley, ML;Spriggs, DR
通讯作者：
Spriggs, DR
影响因子：
4.7
作者：
Goff, BA;delaCuesta, RS;Fuller, AF
通讯作者：
Fuller, AF